-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest research results of WCLC are gratifying, and the follow-up exploration is expected to greatly expand the application scope of savatinib!
Among the emerging therapeutic targets for non-small cell lung cancer (NSCLC) in recent years, MET abnormality is a special category.
At the recently held World Conference on Lung Cancer (WCLC), a number of recent results related to MET amplification/overexpression were announced, including the use of sivotinib + osimertinib combination therapy for EGFR mutation-positive and Results of the Phase II SAVANNAH clinical study in osimertinib-resistant patients
EGFR+MET dual-target therapy shows good strength in cracking resistance to third-generation EGFR-TKIs
Professor Wu Yilong said that the design of the SANOVO study also fully draws on and considers the design and results of the SAVANNAH study
Expert Profile Prof.
President of Guangdong Medical Doctor Association (GDMDA)
Chief Expert of Guangdong Provincial People's Hospital (GDPH)
Honorary Director of Guangdong Lung Cancer Institute (GLCI)
Chairman of China Thoracic Oncology Collaborative Group (CTONG)
2018-2021 Global Highly Cited Scientists in Clinical Medicine
2020 World Conference on Lung Cancer (WCLC) President
Chairman of Guangdong Medical Association Lung Oncology Society
Former Chairman of the Chinese Society of Clinical Oncology, Chairman of the Steering Committee
references:
[1] Sequist LV, Han JY, Ahn MJ, et al.
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre , open-label, phase 1b study[J].
The Lancet Oncology, 2020, 21(3): 373-386.
[2] Ryan Hartmaier, et al.
Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study.
2021 AACR, Abstract CT127.
[3] Ann MJ, et al.
MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib.
WCLC 2022.
EP08.
02-140.
[4] Zhou Q, et al.
SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC.
WCLC 2022.
EP08.
02-063.
Source: Medical community Editor in charge: Zheng HuajuHot text recommendation
* The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
.
Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
.
Click "Read the original text" to see more information~
